Approval · Notice of Compliance 27593 · 2022
BIMZELX: Notice of Compliance 27593
Issued February 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27593
- Date
- February 14, 2022
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- BIMEKIZUMAB 160 MG per ML